|Day Low/High||40.65 / 42.45|
|52 Wk Low/High||8.50 / 43.35|
Designation Based on Positive Results from Study 1, the First Pivotal Phase 3 Trial of ZX008
Investors in Zogenix Inc. saw new options become available this week, for the March 16th expiration.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Zogenix Inc. , where a total of 5,943 contracts have traded so far, representing approximately 594,300 underlying shares.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Zogenix Inc. , where a total of 4,378 contracts have traded so far, representing approximately 437,800 underlying shares.
Until we have some sort of dip, it won't be simple to find new buys.
There is just no logical way to gauge how much further this market can run even when it is technically extended by most measures.
In recent trading, shares of Zogenix Inc. have crossed above the average analyst 12-month target price of $24.67, changing hands for $35.05/share.
Zogenix, Flexion, Dynavax and Progenics all have potential upside on these events.
The S&P 500 reaches new records on Friday, Sept. 29, closing at all-time highs for the second day in a row.
The S&P 500 reaches new records on Friday, Sept. 29, and is on track to close at all-time highs for the second day in a row.
Zogenix, Flexion, Dynavax and Progenics all have potential upside on upcoming events.
Stocks hold mixed on Friday, Sept. 29, as investors look to close out a quarter of geopolitical tension and weather disruption.
The Emeryville, Calif.-based firm said its first Phase 3 study of ZX008 in Dravet syndrome achieved its primary endpoint. Dravet syndrome is a form of epilepsy.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.